Wire · regulatory
Routine Health Data Is Outperforming Trial Data for AI Training. The FDA Hasn't Caught Up.
◆ Sectors
Health
◆ Geography
United States
◆ Source
◆ Verified
Fusion42 · 1 August 2026 · Fusion42 review
A 2026 study shows AI models trained on routine health data outperform those trained on clinical trial data, but FDA regulatory frameworks have not caught up with this shift, creating uncertainty for AI diagnostic tool approvals.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You must rethink validation for AI tools trained on routine health data as FDA rules lag behind their proven performance advantages. This gap opens a strategic window for faster, real-world-data-first AI deployments but risks uncertain regulatory clearance.
◆ Coverage
1 source · 1 Aug 2026
◆ Related on Wire
◆ Topics
Healthroutine-dataclinical-aifda-regulationreal-world-evidencemedical-ai